Response to checkpoint inhibition in lung cancer with molecular driver alterations.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.e21071
Abstract: e21071Background: Checkpoint inhibitors are widely used in NSCLC. While there is evidence that EGFR mutation driven tumours respond poorly to checkpoint inhibition, little is known about the sensit... read more here.
Keywords: response checkpoint; inhibition lung; checkpoint inhibition; lung cancer ... See more keywords